GLP-1 for Cardiovascular Disease Risk

Cardiovascular disease (CVD) — which includes coronary artery disease, heart attack, stroke, heart failure, and peripheral artery disease — is the leading cause of death globally, responsible for an estimated 17.9 million deaths per year. Atherosclerosis, the progressive buildup of lipid-rich plaques in arterial walls, underlies most acute cardiovascular events. Risk factors include hypertension, diabetes, dyslipidemia, smoking, physical inactivity, and obesity.

Obesity is a powerful, independent driver of cardiovascular risk. Excess adipose tissue, particularly visceral fat, promotes chronic low-grade inflammation, insulin resistance, atherogenic dyslipidemia, and elevated blood pressure — each of which accelerates plaque formation and arterial stiffening. For decades, no weight-loss medication was shown to reduce cardiovascular events. In fact, several older anti-obesity drugs were withdrawn from the market after causing cardiac harm.

That landscape changed with GLP-1 receptor agonists. Initially developed for type 2 diabetes, these drugs demonstrated a reduction in major adverse cardiovascular events (MACE) across a series of large, rigorously conducted outcomes trials. In 2024, the FDA granted semaglutide (Wegovy) a dedicated cardiovascular risk-reduction indication based on results in people without diabetes — the first such approval for an obesity medication.

The first evidence emerged from type 2 diabetes cardiovascular outcomes trials (CVOTs) mandated by the FDA after the 2008 rosiglitazone controversy. LEADER (Marso et al., N Engl J Med 2016 [2]) enrolled 9,340 adults with type 2 diabetes and high cardiovascular risk. Over a median follow-up of 3.8 years, liraglutide 1.8 mg reduced the composite of CV death, nonfatal heart attack, and nonfatal stroke (MACE-3) by 13% compared with placebo (HR 0.87, 95% CI 0.78–0.97, p=0.01 for superiority). This was the first GLP-1 trial to demonstrate cardiovascular superiority rather than mere non-inferiority.

SUSTAIN-6 (Marso et al., N Engl J Med 2016 [3]) tested once-weekly semaglutide in 3,297 adults with T2D and high CV risk over two years. Semaglutide reduced MACE by 26% (HR 0.74, 95% CI 0.58–0.95, p=0.02 for superiority), with a particularly notable reduction in nonfatal stroke. REWIND (Gerstein et al., Lancet 2019 [4]) studied dulaglutide in 9,901 T2D patients, including a higher proportion with only moderate CV risk than prior trials. Over a median 5.4 years, dulaglutide reduced MACE by 12% (HR 0.88, 95% CI 0.79–0.99, p=0.026), extending the cardiovascular benefit to a broader T2D population.

A 2019 meta-analysis by Kristensen et al. in the Lancet Diabetes and Endocrinology [5] pooled data from seven GLP-1 CVOT trials and found that, as a class, GLP-1 receptor agonists reduced MACE by 14% (HR 0.86, 95% CI 0.80–0.93), cardiovascular death by 12%, and fatal or nonfatal stroke by 16% in patients with type 2 diabetes at elevated cardiovascular risk. An earlier meta-analysis (Bethel et al., Lancet Diabetes Endocrinol 2018 [6]) reached consistent conclusions. The benefit appeared most consistent among drugs with established atherosclerotic indications.

The SELECT trial (Lincoff et al., N Engl J Med 2023 [1]) was the pivotal extension to people without diabetes. It enrolled 17,604 adults aged 45 or older with established CVD (prior myocardial infarction, stroke, or peripheral artery disease), a BMI of 27 kg/m² or higher, and NO type 2 diabetes. Randomized to semaglutide 2.4 mg weekly or placebo, with a median follow-up of 34.2 months, semaglutide reduced MACE by 20% (HR 0.80, 95% CI 0.72–0.90, p<0.001). Absolute event rates were 6.5% in the semaglutide group versus 8.0% with placebo. Critically, the benefit appeared across prespecified subgroups and diverged early in follow-up, before large differences in body weight had accumulated, suggesting cardiovascular mechanisms beyond simple adiposity reduction. These results led to FDA approval of a cardiovascular risk-reduction indication for Wegovy in March 2024.

Wegovy (semaglutide 2.4 mg) carries a distinct FDA-approved indication to reduce the risk of serious cardiovascular events in adults who have established cardiovascular disease AND either overweight (BMI ≥27 kg/m²) or obesity. Established CVD means a documented history of myocardial infarction, stroke, or symptomatic peripheral artery disease — not merely elevated risk factors or a family history of heart disease. This indication is based directly on the SELECT trial population and is separate from the weight-management indication.

Patients with type 2 diabetes who also have high cardiovascular risk may qualify for CV-labeled GLP-1 formulations used primarily for glucose control: semaglutide (Ozempic), liraglutide (Victoza), and dulaglutide (Trulicity) all carry CVOT-based cardiovascular benefit labeling. The non-diabetic CV indication for Wegovy specifically addresses the gap for overweight/obese patients with established CVD who have not developed diabetes. Primary prevention (CV risk factors without a prior event) is not currently covered under these approved CV indications, and prescribers should frame that distinction clearly with patients.

In SELECT, the cardiovascular benefit was observed on top of standard-of-care therapy: most participants were already taking statins, antihypertensives, and antiplatelet agents. GLP-1 receptor agonists for CV risk reduction are therefore add-on therapy, not replacements for guideline-directed medical therapy. Patients with established CVD should not discontinue proven CV medications in favor of GLP-1 drugs alone. The side-effect profile mirrors the obesity indication: nausea, vomiting, and gastrointestinal discomfort are most common during dose escalation and generally improve over weeks.

The evidence base for GLP-1 drugs in heart failure with reduced ejection fraction (HFrEF) is less established. Dedicated heart failure outcome trials are ongoing. Patients with recent acute coronary syndrome, decompensated heart failure, or significant arrhythmia should initiate GLP-1 therapy in close coordination with a cardiologist. As in all CV risk management, lifestyle modification — dietary improvement, regular physical activity, smoking cessation, and alcohol limitation — remains foundational and is not replaced by pharmacotherapy. Cost and insurance access are real-world barriers, particularly for the 2.4-mg Wegovy dose used in SELECT.